|
spikevax JN.1 is indicated for active immunisation to prevent COVID-19 caused by SARS-CoV-2 in individuals 6 months of age and older. This vaccine should be used in accordance with official recommendations.1 Prescribing information can be found here: Reference 1. spikevax JN.1 50 micrograms dispersion for injection in pre-filled syringe SmPC. Available at: https://www.medicines.org.uk/emc/product/15914/smAccessed: July 2025 |
Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk/ or search for MHRA Yellow Card in the Google Play or Apple App Store and include the vaccine brand and batch/ Lot number if available. They can also be reported to Moderna using the Adverse Events Intake Portal or by calling 0800 085 7562. To report a product quality complaint or for general medical information inquiries, please contact Moderna on 0800 085 7562 or at wecare@modernatx.com. |
| UK-COV-2500043 | July 2025 | |